An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 213135
Company: AZURITY

Medication Guide

Products on NDA 213135

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
SUTAB	MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE	0.225GM;0.188GM;1.479GM	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 213135

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
11/10/2020	ORIG-1	Approval	Type 3 - New Dosage Form	STANDARD; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213135s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213135Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213135Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/24/2023	SUPPL-4	Labeling-Container/Carton Labels, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213135Orig1s004correctedlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213135Orig1s004ltr.pdf
01/28/2022	SUPPL-3	Labeling-Package Insert, Labeling-Medication Guide	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213135s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213135Orig1s003ltr.pdf

Labels for NDA 213135

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/24/2023	SUPPL-4	Labeling-Container/Carton Labels	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213135Orig1s004correctedlbl.pdf
10/24/2023	SUPPL-4	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213135Orig1s004correctedlbl.pdf
01/28/2022	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213135s003lbl.pdf
01/28/2022	SUPPL-3	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213135s003lbl.pdf
11/10/2020	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213135s000lbl.pdf

Therapeutic Equivalents for NDA 213135

SUTAB

TABLET;ORAL; 0.225GM;0.188GM;1.479GM
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE	MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE	0.225GM;0.188GM;1.479GM	TABLET;ORAL	Prescription	No	AB	216095	LUPIN
SUTAB	MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE	0.225GM;0.188GM;1.479GM	TABLET;ORAL	Prescription	Yes	AB	213135	AZURITY

Top